| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Artesunate versus quinine: the controlled trials watershed
|
Keating, Conrad
|
|
|
401 |
10385 |
p. 1329-1331
|
article
|
| 2 |
Assessing COVID-19 pandemic policies and behaviours and their economic and educational trade-offs across US states from Jan 1, 2020, to July 31, 2022: an observational analysis
|
Bollyky, Thomas J
|
|
|
401 |
10385 |
p. 1341-1360
|
article
|
| 3 |
Barbara C Staggers
|
Green, Andrew
|
|
|
401 |
10385 |
p. 1334
|
article
|
| 4 |
Clinical aspects of snakebite envenoming and its treatment in low-resource settings
|
Warrell, David A
|
|
|
401 |
10385 |
p. 1382-1398
|
article
|
| 5 |
Decentralised elements in clinical trials: recommendations from the European Medicines Regulatory Network
|
Al, Monique
|
|
|
401 |
10385 |
p. 1339
|
article
|
| 6 |
Department of Error
|
|
|
|
401 |
10385 |
p. 1340
|
article
|
| 7 |
Drug developers caution against US mifepristone ban
|
Jaffe, Susan
|
|
|
401 |
10385 |
p. 1325-1326
|
article
|
| 8 |
Endovascular treatment versus no endovascular treatment after 6–24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial
|
Olthuis, Susanne G H
|
|
|
401 |
10385 |
p. 1371-1380
|
article
|
| 9 |
Evaluating the impact of alcohol minimum unit pricing on deaths and hospitalisations in Scotland: a controlled interrupted time series study
|
Wyper, Grant M A
|
|
|
401 |
10385 |
p. 1361-1370
|
article
|
| 10 |
Even more benefit with endovascular treatment for patients with acute ischaemic stroke: MR CLEAN-LATE
|
Wardlaw, Joanna M
|
|
|
401 |
10385 |
p. 1317-1319
|
article
|
| 11 |
Fluid retention and heart failure in the PRECISION trial
|
Kohan, Donald E
|
|
|
401 |
10385 |
p. 1335
|
article
|
| 12 |
Fluid retention and heart failure in the PRECISION trial – Authors' reply
|
Schlaich, Markus P
|
|
|
401 |
10385 |
p. 1335-1336
|
article
|
| 13 |
Improving access to global cancer services
|
Mahajan, Arnav
|
|
|
401 |
10385 |
p. 1338-1339
|
article
|
| 14 |
Key questions regarding the SYMPLICITY HTN-3 trial
|
Tanemoto, Masayuki
|
|
|
401 |
10385 |
p. 1337
|
article
|
| 15 |
Key questions regarding the SYMPLICITY HTN-3 trial
|
Kjeldsen, Sverre E
|
|
|
401 |
10385 |
p. 1336-1337
|
article
|
| 16 |
Key questions regarding the SYMPLICITY HTN-3 trial – Authors' reply
|
Bhatt, Deepak L
|
|
|
401 |
10385 |
p. 1337-1338
|
article
|
| 17 |
Lessons learned from COVID-19 to stop future pandemics
|
Cueni, Thomas
|
|
|
401 |
10385 |
p. 1340
|
article
|
| 18 |
Minimum unit pricing for alcohol targets harms experienced by people in lower socioeconomic groups in Scotland
|
Callinan, Sarah
|
|
|
401 |
10385 |
p. 1315-1317
|
article
|
| 19 |
Offline: The UK COVID-19 Inquiry—be patient, but don’t wait
|
Horton, Richard
|
|
|
401 |
10385 |
p. 1324
|
article
|
| 20 |
Promote global solidarity to advance health-system resilience: proposals for the G7 meetings in Japan
|
|
|
|
401 |
10385 |
p. 1319-1321
|
article
|
| 21 |
Racism, xenophobia, and discrimination: data disaggregation is a complex but crucial step to improving child health
|
Devakumar, Delan
|
|
|
401 |
10385 |
p. 1321-1323
|
article
|
| 22 |
Rare diseases: democratising genetic testing in LMICs
|
Núñez-Samudio, Virginia
|
|
|
401 |
10385 |
p. 1339-1340
|
article
|
| 23 |
Routine immunisations: reversing the decline
|
The Lancet,
|
|
|
401 |
10385 |
p. 1313
|
article
|
| 24 |
State-to-state differences in US COVID-19 outcomes: searching for explanations
|
Lurie, Nicole
|
|
|
401 |
10385 |
p. 1314-1315
|
article
|
| 25 |
Transcriptomics aids differentiation of IL-23 overactivity in a patient with atypical skin and joint disease
|
Hakimi, Marwa
|
|
|
401 |
10385 |
p. 1381
|
article
|
| 26 |
Uganda's “anti-homosexuality” bill already affecting care
|
Jerving, Sara
|
|
|
401 |
10385 |
p. 1327-1328
|
article
|
| 27 |
Visual representation, medicine, and imperialism
|
Chatterjee, Apurba
|
|
|
401 |
10385 |
p. 1332-1333
|
article
|
Journal description